The Dilemma of Two Innovative Therapies for #SMAhttps://t.co/j8pb7J7obS$AVXShttps://t.co/mMFXFW0ohC$BIIB $IONShttps://t.co/P12WQt0ftd
— Andy Biotech (@AndyBiotech) November 2, 2017
Gut #microbiome can shape response to anti-PD1 cancer #immunotherapyhttps://t.co/zNKWX7Xhwrhttps://t.co/QljXKmUWDvhttps://t.co/I9dDTZTA0b pic.twitter.com/M02brrzQLy
— Andy Biotech (@AndyBiotech) November 2, 2017
The pipeline and market for atopic dermatitis therapies https://t.co/1FrOHBnGO7 pic.twitter.com/55YlTM6UIF
— Nature Rev Drug Disc (@NatRevDrugDisc) November 9, 2017
Two NEJM Perspectives on Germline #GeneEditing
— Andy Biotech (@AndyBiotech) November 16, 2017
Compelling Reasons for Repairing Human Germlines
by @geochurch https://t.co/DBdlTiskav
Designing Ethical Trials of Germline Gene Editing
by @bpcwik https://t.co/egDnz5xItX pic.twitter.com/4Xt5PhAekE
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis — NEJM https://t.co/ry0RiF5IIs
— Pierre Bedard (@PRB51) November 23, 2017
Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes https://t.co/eKAntFjZYw
— Tom Silver (@TomSilver39) November 23, 2017
“This isn’t just a new treatment, this is a new approach to treating #cancer,” - David Porter @PennMedicine @PennCancer in The Promise and Challenges of CAR #TCell Gene Therapy https://t.co/fBwFmWMSft
— Bruce Levine (@BLLPHD) November 29, 2017
Cool effort to evaluate spectrum of inhibition of clinically available kinase inhibitors https://t.co/LN810P7sg1 pic.twitter.com/hmSYnkRP4G
— Gregory Riely (@RielyMD) November 30, 2017
As debate rumbles on about how and how much poor statistics is to blame for poor reproducibility, Nature asked influential statisticians to recommend one change to improve science. The common theme? The problem is not our maths, but ourselves https://t.co/QlocQ6DwdM
— nature (@nature) December 2, 2017
Gene therapy shows promise against blood-clotting disease https://t.co/Sl9tvAgCKe $ONCE $BMRN $SGMO Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant — NEJM https://t.co/fkqkuXDFGv
— Tom Silver (@TomSilver39) December 8, 2017
Ups, Biotech did it again.
— Bursatil Biotech (@BursatilBiotech) December 9, 2017
A cure for Hemophilia within reach.
Beautiful. https://t.co/8moeOOtB5K
A #CRISPR/Cas9 system transcriptionally activates endogenous target genes in vivo. The system ameliorates symptoms associated with several mouse models of human #diseases. Free article --> https://t.co/te1O6NtxpC pic.twitter.com/GXmwKwCKO7
— Cell at CellPress (@CellCellPress) December 9, 2017
Amazing paper in CELL Pharmacogenomics of GPCR Drug Targets https://t.co/X8nfoSBKfO
— BryanRoth (@zenbrainest) December 14, 2017